Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil ploughs US$3.6 million into TB (tuberculosis) detection:

This article was originally published in Clinica

Executive Summary

The Brazilian health ministry has allocated R$11.1m (US$3.6m) in 2002 to a programme of incentives to promote the detection of tuberculosis (TB). The funding, up R$3.5m since 2001, will be used to encourage implementation of the World Health Organization's directly observed treatment strategy (DOTS), which involves diagnostic testing for the disease and prognostic monitoring of treatment. Some 20% of the estimated 120,000 TB patients in Brazil are monitored under DOTS. Brazil aims to raise this to 50% by 2003 and 100% by 2005, principally in the 329 municipalities most severely affected by the disease. Under the ministry's incentives scheme, each municipality will receive R$50 for every new case diagnosed and R$200 for every patient treated. Some 82,000 new cases are diagnosed every year. TB is a priority areas for the WHO, which believes that the disease kills some two million people every year (see this page).

You may also be interested in...



Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel